Real-world data of Azvudine-induced hepatotoxicity among hospitalized COVID-19 patients in China: a retrospective case-control study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study found that Azvudine treatment for COVID-19 is associated with significant hepatotoxicity in hospitalized patients. Monitoring liver function and caution with certain co-administered drugs are crucial during Azvudine therapy.
Area Of Science
- Hepatology
- Infectious Diseases
- Pharmacology
Background
- The COVID-19 pandemic necessitates effective treatments, with antiviral drugs like Azvudine showing promise.
- However, the safety profile of Azvudine, particularly concerning liver toxicity (hepatotoxicity), requires thorough investigation in real-world clinical settings.
- Understanding Azvudine-induced hepatotoxicity is crucial for optimizing patient care during the SARS-CoV-2 pandemic.
Purpose Of The Study
- To evaluate the prevalence and risk factors of Azvudine-associated hepatotoxicity in hospitalized COVID-19 patients.
- To characterize the clinical patterns and outcomes of Azvudine-induced liver injury.
- To identify predictors and associated medications contributing to Azvudine hepatotoxicity.
Main Methods
- A single-center retrospective case-control study was conducted at Renmin Hospital of Wuhan University.
- 669 patients treated with Azvudine for COVID-19 between December 2022 and May 2023 were analyzed.
- Logistic regression and ROC curve analyses were employed to identify risk factors and assess predictive value.
Main Results
- 47.1% of patients exhibited Azvudine-associated hepatotoxicity; abnormal liver function on admission and antithrombotic drugs were independent predictors.
- Among 294 cases studied for induced hepatotoxicity, 27.2% showed liver injury, with concomitant antivirals (especially Ganciclovir) and anticoagulants (LMWH, Enoxaparin) significantly increasing risk.
- Most cases were mild and resolved upon drug withdrawal, but severe instances correlated with disease progression and increased mortality.
Conclusions
- Azvudine treatment is significantly associated with hepatotoxicity in hospitalized COVID-19 patients.
- Close monitoring of liver function and careful consideration of concomitant medications, particularly anticoagulants and other antivirals, are essential.
- Further research is needed to elucidate mechanisms and refine clinical management strategies for Azvudine-induced liver injury.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
• Ventilation-Perfusion (V/Q)...